MannKind Inhaler

New Potential Insulin Inhaler Developed

Categories: Current Research

This is an exciting time for all diabetics that use medicinal insulin to regulate their blood sugar. MannKind Corporation, a development stage biopharmaceutical company, is putting high stakes on the new technology for diabetics.

As a much sought-after alternative to annoying shots, the inhaler would drastically increase the quality of life for diabetics. This more convenient method would bypass injections by delivering insulin through the lungs. The powder, called “Afrezza” showed positive results in a late-stage clinical trial for regulating long-term blood sugar levels. Two pharmaceutical giants, Pfizer and Novo Nordisk, have previously attempted to make insulin inhalers a success but came short – when brought to the marketplace, insurers claimed that the drug was too expensive and not effective enough. MannKind Corporation found a solution to this problem, suggesting that the annual cost of the inhaler could match the current cost of pen needles and syringes – about $2000.

Alfred Mann, chairman and CEO of the corporation has invested $930 million of his own money to pursue the signature product. Him and his executive staff realize the immense and always growing market for diabetes. In fact, America’s 8% of the population being diabetic does not even put the country on the top 10 list for highest incidences of diabetes. Because of this, the stock prices of the company soared 25% the day the news announced as investors are most focused on Afrezza. The company plans to present data to the FDA in just a short couple months and hopes to be able to release the drugs onto the market by second quarter, 2014. Until we find an alternative, know that you can find great prices on EasyTouch Pen Needles and Syringes at DiabeticCare.com.

By: DiabeticCare editorial team; Published: 8-30-2013, 2:00 PM

Leave a Comment




© 2017 DiabeticCare Blog